|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HECTD1 |
Gene summary for HECTD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HECTD1 | Gene ID | 25831 |
| Gene name | HECT domain E3 ubiquitin protein ligase 1 | |
| Gene Alias | EULIR | |
| Cytomap | 14q12 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9ULT8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 25831 | HECTD1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.06e-19 | -5.59e-01 | 0.0155 |
| 25831 | HECTD1 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.18e-05 | 4.85e-01 | -0.1954 |
| 25831 | HECTD1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 4.17e-09 | -5.29e-01 | -0.1207 |
| 25831 | HECTD1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 6.67e-03 | -5.25e-01 | -0.2061 |
| 25831 | HECTD1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 5.99e-06 | -4.19e-01 | 0.3859 |
| 25831 | HECTD1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.98e-03 | -5.06e-01 | 0.2585 |
| 25831 | HECTD1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 5.90e-08 | -4.61e-01 | 0.3005 |
| 25831 | HECTD1 | F007 | Human | Colorectum | FAP | 3.76e-04 | -3.83e-01 | 0.1176 |
| 25831 | HECTD1 | A001-C-207 | Human | Colorectum | FAP | 1.15e-03 | -1.84e-01 | 0.1278 |
| 25831 | HECTD1 | A015-C-203 | Human | Colorectum | FAP | 3.58e-31 | -3.49e-01 | -0.1294 |
| 25831 | HECTD1 | A015-C-204 | Human | Colorectum | FAP | 9.65e-05 | -2.46e-01 | -0.0228 |
| 25831 | HECTD1 | A014-C-040 | Human | Colorectum | FAP | 6.94e-05 | -3.05e-01 | -0.1184 |
| 25831 | HECTD1 | A002-C-201 | Human | Colorectum | FAP | 1.46e-15 | -3.66e-01 | 0.0324 |
| 25831 | HECTD1 | A002-C-203 | Human | Colorectum | FAP | 1.05e-06 | -1.69e-01 | 0.2786 |
| 25831 | HECTD1 | A001-C-119 | Human | Colorectum | FAP | 2.16e-05 | -1.45e-01 | -0.1557 |
| 25831 | HECTD1 | A001-C-108 | Human | Colorectum | FAP | 1.47e-19 | -1.75e-01 | -0.0272 |
| 25831 | HECTD1 | A002-C-205 | Human | Colorectum | FAP | 6.00e-25 | -1.93e-01 | -0.1236 |
| 25831 | HECTD1 | A001-C-104 | Human | Colorectum | FAP | 1.80e-02 | -7.51e-02 | 0.0184 |
| 25831 | HECTD1 | A015-C-005 | Human | Colorectum | FAP | 1.02e-09 | -4.07e-01 | -0.0336 |
| 25831 | HECTD1 | A015-C-006 | Human | Colorectum | FAP | 3.28e-16 | -4.08e-01 | -0.0994 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00018387 | Prostate | BPH | embryonic epithelial tube formation | 36/3107 | 121/18723 | 2.20e-04 | 1.78e-03 | 36 |
| GO:19031315 | Prostate | BPH | mononuclear cell differentiation | 98/3107 | 426/18723 | 3.43e-04 | 2.55e-03 | 98 |
| GO:00163314 | Prostate | BPH | morphogenesis of embryonic epithelium | 41/3107 | 147/18723 | 3.86e-04 | 2.83e-03 | 41 |
| GO:00018419 | Prostate | BPH | neural tube formation | 31/3107 | 102/18723 | 3.87e-04 | 2.84e-03 | 31 |
| GO:00721757 | Prostate | BPH | epithelial tube formation | 37/3107 | 132/18723 | 6.52e-04 | 4.42e-03 | 37 |
| GO:00032813 | Prostate | BPH | ventricular septum development | 23/3107 | 71/18723 | 7.95e-04 | 5.21e-03 | 23 |
| GO:0003231 | Prostate | BPH | cardiac ventricle development | 34/3107 | 123/18723 | 1.37e-03 | 8.20e-03 | 34 |
| GO:00032792 | Prostate | BPH | cardiac septum development | 29/3107 | 103/18723 | 2.20e-03 | 1.22e-02 | 29 |
| GO:00140207 | Prostate | BPH | primary neural tube formation | 27/3107 | 94/18723 | 2.25e-03 | 1.24e-02 | 27 |
| GO:00032052 | Prostate | BPH | cardiac chamber development | 41/3107 | 161/18723 | 2.63e-03 | 1.41e-02 | 41 |
| GO:00300982 | Prostate | BPH | lymphocyte differentiation | 83/3107 | 374/18723 | 2.76e-03 | 1.46e-02 | 83 |
| GO:00018436 | Prostate | BPH | neural tube closure | 25/3107 | 88/18723 | 3.76e-03 | 1.89e-02 | 25 |
| GO:00606065 | Prostate | BPH | tube closure | 25/3107 | 89/18723 | 4.43e-03 | 2.17e-02 | 25 |
| GO:00219157 | Prostate | BPH | neural tube development | 38/3107 | 152/18723 | 5.14e-03 | 2.42e-02 | 38 |
| GO:19030776 | Prostate | BPH | negative regulation of protein localization to plasma membrane | 9/3107 | 24/18723 | 1.14e-02 | 4.64e-02 | 9 |
| GO:004217619 | Prostate | Tumor | regulation of protein catabolic process | 142/3246 | 391/18723 | 9.32e-20 | 5.79e-17 | 142 |
| GO:001049819 | Prostate | Tumor | proteasomal protein catabolic process | 158/3246 | 490/18723 | 3.05e-16 | 6.76e-14 | 158 |
| GO:000989619 | Prostate | Tumor | positive regulation of catabolic process | 155/3246 | 492/18723 | 5.62e-15 | 8.52e-13 | 155 |
| GO:190336219 | Prostate | Tumor | regulation of cellular protein catabolic process | 95/3246 | 255/18723 | 1.92e-14 | 2.54e-12 | 95 |
| GO:004586219 | Prostate | Tumor | positive regulation of proteolysis | 124/3246 | 372/18723 | 3.46e-14 | 4.31e-12 | 124 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HECTD1 | SNV | Missense_Mutation | c.6715N>A | p.Glu2239Lys | p.E2239K | Q9ULT8 | protein_coding | tolerated(0.11) | probably_damaging(0.973) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| HECTD1 | SNV | Missense_Mutation | c.140N>G | p.Thr47Arg | p.T47R | Q9ULT8 | protein_coding | deleterious(0.01) | benign(0.148) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HECTD1 | SNV | Missense_Mutation | c.2228N>G | p.Pro743Arg | p.P743R | Q9ULT8 | protein_coding | deleterious(0) | possibly_damaging(0.896) | TCGA-A8-A08P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| HECTD1 | SNV | Missense_Mutation | c.5992G>C | p.Glu1998Gln | p.E1998Q | Q9ULT8 | protein_coding | deleterious(0.01) | benign(0.115) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| HECTD1 | SNV | Missense_Mutation | rs755152978 | c.3005N>A | p.Arg1002Gln | p.R1002Q | Q9ULT8 | protein_coding | deleterious(0) | probably_damaging(0.916) | TCGA-A8-A09W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| HECTD1 | SNV | Missense_Mutation | rs748524391 | c.4411N>T | p.Arg1471Cys | p.R1471C | Q9ULT8 | protein_coding | deleterious(0.02) | benign(0.336) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HECTD1 | SNV | Missense_Mutation | c.1259N>T | p.Ala420Val | p.A420V | Q9ULT8 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | |
| HECTD1 | SNV | Missense_Mutation | c.1510G>A | p.Glu504Lys | p.E504K | Q9ULT8 | protein_coding | tolerated(0.26) | benign(0.009) | TCGA-AR-A0TP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| HECTD1 | SNV | Missense_Mutation | c.4696C>G | p.Leu1566Val | p.L1566V | Q9ULT8 | protein_coding | tolerated(0.29) | probably_damaging(0.931) | TCGA-B6-A0RG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| HECTD1 | SNV | Missense_Mutation | novel | c.3858N>T | p.Trp1286Cys | p.W1286C | Q9ULT8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |